Dry powder treprostinil for the treatment of pulmonary hypertension
US11712442B2 · kind B2 · utility
0Cited by
44References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 25, 2020 |
| Grant date | Aug 1, 2023 |
| Priority date | — |
| Expiry date | Nov 25, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.